In breast cancer, the PD-1/PD-L1 axis is particularly important, so that atezolizumab, for example, a monoclonal antibody against PD-L1, in combination with nab-paclitaxel, is an approved therapeutic option in advanced triple-negative breast cancer [9]. This evidence concerns the gene PDCD1 and triple-negative breast carcinoma.